CA3068588A1 - Methods of treating heart failure with cardiac sarcomere activators - Google Patents

Methods of treating heart failure with cardiac sarcomere activators Download PDF

Info

Publication number
CA3068588A1
CA3068588A1 CA3068588A CA3068588A CA3068588A1 CA 3068588 A1 CA3068588 A1 CA 3068588A1 CA 3068588 A CA3068588 A CA 3068588A CA 3068588 A CA3068588 A CA 3068588A CA 3068588 A1 CA3068588 A1 CA 3068588A1
Authority
CA
Canada
Prior art keywords
subject
dose
csa
time period
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3068588A
Other languages
English (en)
French (fr)
Inventor
Narimon HONARPOUR
Fady Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Cytokinetics Inc
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of CA3068588A1 publication Critical patent/CA3068588A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3068588A 2017-06-30 2018-06-29 Methods of treating heart failure with cardiac sarcomere activators Pending CA3068588A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Publications (1)

Publication Number Publication Date
CA3068588A1 true CA3068588A1 (en) 2019-01-03

Family

ID=63013097

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3068588A Pending CA3068588A1 (en) 2017-06-30 2018-06-29 Methods of treating heart failure with cardiac sarcomere activators

Country Status (22)

Country Link
US (4) US11576910B2 (enExample)
EP (2) EP4512470A3 (enExample)
JP (3) JP2020526483A (enExample)
CN (1) CN110996953A (enExample)
AU (2) AU2018290983B2 (enExample)
BR (1) BR112019028046A2 (enExample)
CA (1) CA3068588A1 (enExample)
DK (1) DK3645002T3 (enExample)
ES (1) ES3008457T3 (enExample)
FI (1) FI3645002T3 (enExample)
HR (1) HRP20241729T1 (enExample)
HU (1) HUE069805T2 (enExample)
LT (1) LT3645002T (enExample)
MA (1) MA49508B1 (enExample)
MD (1) MD3645002T2 (enExample)
MX (2) MX2020000190A (enExample)
PL (1) PL3645002T3 (enExample)
PT (1) PT3645002T (enExample)
RS (1) RS66581B1 (enExample)
SI (1) SI3645002T1 (enExample)
SM (1) SMT202500067T1 (enExample)
WO (1) WO2019006235A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
CA3138080A1 (en) * 2019-05-19 2020-11-26 Jean-Francois TAMBY Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid
CA3168513A1 (en) * 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
IL298885A (en) * 2020-06-15 2023-02-01 Myokardia Inc Treatment of atrial function
TW202233189A (zh) * 2020-11-12 2022-09-01 美商安進公司 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
IL319671A (en) 2022-09-26 2025-05-01 Edgewise Therapeutics Inc 4,1-Dihydroquinazolinone compounds and their uses
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス， インコーポレイテッド キナゾリンジオン化合物およびその使用
EP4688748A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
AU2546399A (en) 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
WO2007133747A2 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd BIODEGRADABLE MICRO BEADS COMPOSITION FOR CONTROLLED RELEASE OF GLUCOSE-CONTROLLED PEPTIDE AND FORMULATION THEREOF
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
AU2014240104B2 (en) * 2013-03-14 2018-11-08 Amgen Inc. Heterocyclic compounds and their uses
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
US20200087367A1 (en) 2017-02-06 2020-03-19 Acceleron Pharma Inc. Compositions and methods for treating heart failure
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
EP3599243B1 (en) 2018-07-26 2023-04-12 CVIE Therapeutics Limited 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
EP3934654B1 (en) 2019-03-05 2026-04-29 Windtree Therapeutics, Inc. Istaroxime or its metabolite pst-3093 for use as intravenous formulation for the treatment of acute heart failure (ahf)
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
US20220402874A1 (en) 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
CN114945372A (zh) 2019-11-10 2022-08-26 迈奥卡迪亚公司 用肌球蛋白调节剂的治疗方法
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
CA3168513A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
TW202233189A (zh) 2020-11-12 2022-09-01 美商安進公司 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
EP4512470A2 (en) 2025-02-26
HRP20241729T1 (hr) 2025-03-14
EP4512470A3 (en) 2025-04-23
MA49508B1 (fr) 2024-12-31
WO2019006235A1 (en) 2019-01-03
MD3645002T2 (ro) 2025-04-30
PT3645002T (pt) 2025-01-24
US20250255862A1 (en) 2025-08-14
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
JP2023088944A (ja) 2023-06-27
US20230355615A1 (en) 2023-11-09
HUE069805T2 (hu) 2025-04-28
MX2020000190A (es) 2020-07-22
US20230149394A1 (en) 2023-05-18
DK3645002T3 (da) 2024-12-16
AU2018290983B2 (en) 2023-11-23
SI3645002T1 (sl) 2025-03-31
PL3645002T3 (pl) 2025-03-24
US12295952B2 (en) 2025-05-13
JP2020526483A (ja) 2020-08-31
EP3645002B1 (en) 2024-10-30
JP2025165979A (ja) 2025-11-05
US11576910B2 (en) 2023-02-14
FI3645002T3 (fi) 2025-01-29
SMT202500067T1 (it) 2025-03-12
US11931358B2 (en) 2024-03-19
US20200155547A1 (en) 2020-05-21
MX2022015115A (es) 2023-01-18
ES3008457T3 (en) 2025-03-24
LT3645002T (lt) 2025-02-10
MA49508A (fr) 2020-05-06
AU2024200991A1 (en) 2024-03-07
EP3645002A1 (en) 2020-05-06
CN110996953A (zh) 2020-04-10
RS66581B1 (sr) 2025-04-30
AU2024200991B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
AU2024200991B2 (en) Methods of treating heart failure with cardiac sarcomere activators
Sayin et al. Left ventricular hypertrophy: etiology-based therapeutic options
US12194039B2 (en) Methods of treating heart failure by administering omecamtiv mecarbil
Von Lueder et al. New medical therapies for heart failure
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
US20110230552A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack
KR20250050043A (ko) 비폐쇄성 비대심근병증 치료 방법
Yuyun et al. Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review
Murdoch et al. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects
Bernier et al. Cardiac myosin activation for the treatment of systolic heart failure
Cada et al. Sacubitril/valsartan
US20260041679A1 (en) Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat
KR20250056200A (ko) 폐쇄성 비대심장근육병증 치료 방법
HK40028258B (en) Methods of treating heart failure with cardiac sarcomere activators
HK40028258A (en) Methods of treating heart failure with cardiac sarcomere activators
HK40027649A (en) Methods of treating heart failure with cardiac sarcomere activators
Kato et al. Inefficacy of a Highly Selective T‐Type Calcium Channel Blocker in Preventing Atrial Fibrillation Related Remodeling
KR20210032437A (ko) 심부전의 치료를 위한 신규한 약제학적 용도
Ahmed et al. Sacubitril/Valsartan: A Novel Approach in the Treatment of Heart Failure with Reduced Ejection Fraction
Finimundi et al. Effect of diuretic therapy on exercise capacity in patients with chronic angina and preserved left ventricular function
Hamdy et al. Why Pillar Directed Therapy Does Not Provide Absolute Protection in Heart Failure? The Five Pillars of the Management of Heart Failure
Sabharwal et al. Effect of imidapril and nifedipine on left ventricular hypertrophy in untreated hypertension
TW201134818A (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation
Gibler New Drug Evaluation: sacubitril/valsartan tablet, oral

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220909

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250530

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250606

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250606

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250919

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251126

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251126